Siegel, R. L., Miller, K. D., Wagle, N. S. & Jemal, A. Cancer statistics, 2023. CA Cancer J. Clin. 73, 17–48 (2023).

Article  PubMed  Google Scholar 

SEER*Explorer Application. All cancer sites combined. Recent trends in SEER age-adjusted incidence rates, 2000–2020. https://seer.cancer.gov/statistics-network/explorer/application.html?site=1&data_type=1&graph_type=2&compareBy=sex&chk_sex_3=3&chk_sex_2=2&rate_type=2&race=1&age_range=1&hdn_stage=101&advopt_precision=1&advopt_show_ci=on&hdn_view=0&advopt_show_apc=on&advopt_display=2#resultsRegion0 (2020).

Slomovitz, B., de Haydu, C., Taub, M., Coleman, R. L. & Monk, B. J. Asbestos and ovarian cancer: examining the historical evidence. Int. J. Gynecol. Cancer 31, 122–128 (2021).

Article  PubMed  Google Scholar 

Vachon, C. M. et al. Association of parity and ovarian cancer risk by family history of breast or ovarian cancer in a population-based study of postmenopausal women. Epidemiol. Camb. Mass. 13, 66–71 (2002).

Article  Google Scholar 

Cancer and Steroid Hormone Study of the Centers for Disease Control and the National Institute of Child Health and Human Development. The reduction in risk of ovarian cancer associated with oral-contraceptive use. N. Engl. J. Med. 316, 650–655 (1987).

Article  Google Scholar 

Liu, Y. L. et al. Risk-reducing bilateral salpingo-oophorectomy for ovarian cancer: a review and clinical guide for hereditary predisposition genes. JCO Oncol. Pract. 18, 201–209 (2022).

Article  PubMed  Google Scholar 

Permuth-Wey, J. & Sellers, T. A. Epidemiology of ovarian cancer. Cancer Epidemiol. 472, 413–437 (2009).

Article  Google Scholar 

Ngoi, N. Y. L. & Tan, D. S. P. The role of homologous recombination deficiency testing in ovarian cancer and its clinical implications: do we need it? ESMO Open. 6, 100144 (2021).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Bell, D. et al. Integrated genomic analyses of ovarian carcinoma. Nature 474, 609–615 (2011).

Article  CAS  Google Scholar 

Vázquez-García, I. et al. Ovarian cancer mutational processes drive site-specific immune evasion. Nature 612, 778–786 (2022).

Article  PubMed  PubMed Central  Google Scholar 

Brutovský, B. Scales of cancer evolution: selfish genome or cooperating cells? Cancers 14, 3253 (2022).

Article  PubMed  PubMed Central  Google Scholar 

Hu, Z. et al. The repertoire of serous ovarian cancer non-genetic heterogeneity revealed by single-cell sequencing of normal fallopian tube epithelial cells. Cancer Cell 37, 226–242.e7 (2020).

Article  CAS  PubMed  Google Scholar 

Ishak, C. A., Lheureux, S. & De Carvalho, D. D. DNA methylation as a robust classifier of epithelial ovarian cancer. Clin. Cancer Res. 25, 5729–5731 (2019).

Article  CAS  PubMed  Google Scholar 

Bodelon, C. et al. Molecular classification of epithelial ovarian cancer based on methylation profiling: evidence for survival heterogeneity. Clin. Cancer Res. 25, 5937–5946 (2019).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Höhn, A. K. et al. WHO classification of female genital tumors. Geburtshilfe Frauenheilkd. 81, 1145–1153 (2021). 2020.

Article  PubMed  PubMed Central  Google Scholar 

Prat, J., D’Angelo, E. & Espinosa, I. Ovarian carcinomas: at least five different diseases with distinct histological features and molecular genetics. Hum. Pathol. 80, 11–27 (2018).

Article  CAS  PubMed  Google Scholar 

Peres, L. C. et al. Invasive epithelial ovarian cancer survival by histotype and disease stage. J. Natl Cancer Inst. 111, 60–68 (2019).

Article  PubMed  Google Scholar 

Meinhold-Heerlein, I. et al. Statement by the kommission ovar of the AGO: the new FIGO and WHO classifications of ovarian, fallopian tube and primary peritoneal cancer. Geburtshilfe Frauenheilkd. 75, 1021–1027 (2015).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Hanley, G. E. et al. Outcomes from opportunistic salpingectomy for ovarian cancer prevention. JAMA Netw. Open. 5, e2147343 (2022).

Article  PubMed  PubMed Central  Google Scholar 

Chen, S. et al. A review of the clinical characteristics and novel molecular subtypes of endometrioid ovarian cancer. Front. Oncol. 11, 668151 (2021).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Zhu, C. et al. Clinical characteristics and prognosis of ovarian clear cell carcinoma: a 10-year retrospective study. BMC Cancer 21, 322 (2021).

Article  PubMed  PubMed Central  Google Scholar 

Montag, A. G. et al. Ovarian clear cell carcinoma. A clinicopathologic analysis of 44 cases. Int. J. Gynecol. Pathol. 8, 85–96 (1989).

Article  CAS  PubMed  Google Scholar 

Bolton, K. L. et al. Molecular subclasses of clear cell ovarian carcinoma and their impact on disease behavior and outcomes. Clin. Cancer Res. 28, 4947–4956 (2022).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Lheureux, S. Multi-omics uncovering different faces of clear cell ovarian cancer. Clin. Cancer Res. 28, 4838–4839 (2022).

Article  PubMed  Google Scholar 

Manning-Geist, B. et al. MAPK pathway genetic alterations are associated with prolonged overall survival in low-grade serous ovarian carcinoma. Clin. Cancer Res. 28, 4456–4465 (2022).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Veneziani, A. C. & Oza, A. M. Taking the road less traveled: following molecular trail markers. Clin. Cancer Res. 28, 4357–4359 (2022).

Article  PubMed  Google Scholar 

Morice, P., Gouy, S. & Leary, A. Mucinous ovarian carcinoma. N. Engl. J. Med. 380, 1256–1266 (2019).

Article  CAS  PubMed  Google Scholar 

Babaier, A. & Ghatage, P. Mucinous cancer of the ovary: overview and current status. Diagnostics 10, 52 (2020).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Tischkowitz, M. et al. Small-cell carcinoma of the ovary, hypercalcemic type-genetics, new treatment targets, and current management guidelines. Clin. Cancer Res. 26, 3908–3917 (2020).

Article  CAS  PubMed  PubMed Central  Google Scholar 

McCluggage, W. G., Witkowski, L., Clarke, B. A. & Foulkes, W. D. Clinical, morphological and immunohistochemical evidence that small-cell carcinoma of the ovary of hypercalcaemic type (SCCOHT) may be a primitive germ-cell neoplasm. Histopathology 70, 1147–1154 (2017).

Article  PubMed  Google Scholar 

Bieging, K. T., Mello, S. S. & Attardi, L. D. Unravelling mechanisms of p53-mediated tumour suppression. Nat. Rev. Cancer 14, 359–370 (2014).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Ahmed, A. A. et al. Driver mutations in TP53 are ubiquitous in high grade serous carcinoma of the ovary. J. Pathol. 221, 49–56 (2010).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Li, X. & Heyer, W.-D. Homologous recombination in DNA repair and DNA damage tolerance. Cell Res. 18, 99–113 (2008).

Article  CAS  PubMed  Google Scholar 

Bowtell, D. D. et al. Rethinking ovarian cancer II: reducing mortality from high-grade serous ovarian cancer. Nat. Rev. Cancer 15, 668–679 (2015).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Kroeger, P. T. & Drapkin, R. Pathogenesis and heterogeneity of ovarian cancer. Curr. Opin. Obstet. Gynecol. 29, 26–34 (2017).

Article  PubMed  Google Scholar 

Etemadmoghadam, D. et al. Amplicon-dependent CCNE1 expression is critical for clonogenic survival after cisplatin treatment and is correlated with 20q11 gain in ovarian cancer. PLoS ONE 5, e15498 (2010).

Article  PubMed  PubMed Central  Google Scholar 

Lheureux, S., Braunstein, M. & Oza, A. M. Epithelial ovarian cancer: evolution of management in the era of precision medicine. Ca. Cancer J. Clin. 69, 280–304 (2019).

Article  PubMed  Google Scholar 

Veneziani, A. C., Scott, C., Wakefield, M. J., Tinker, A. V. & Lheureux, S. Fighting resistance: post-PARP inhibitor treatment strategies in ovarian cancer. Ther. Adv. Med. Oncol. 15, 17588359231157644 (2023).

Article  PubMed  PubMed Central  Google Scholar 

Matulonis, U. A. et al. Ovarian cancer. Nat. Rev. Dis. Prim. 2, 16061 (2016).

Article  PubMed